Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC1187 | TNBC | Basal A | LY294002 | PI3K | PI3K | 7812.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0475 | -56.7271 | 0.9642 | |
CAMA-1 | HR+ | Luminal | Ribavirin | 15348.211 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0410 | -5.7835 | 0.7490 | |||
HCC1187 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 10753.154 | uM | inf | inf | 1.0162 | 1.0162 | 0.0000 | -0.0376 | -5.9291 | 1.4444 | |
LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 10380.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0461 | -60.9713 | 1.4916 | |
Hs 578T | TNBC | Basal B | AG1024 | IGF1R | RTK | 7473.066 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0434 | -6.5378 | 2.3582 | |
MDA-MB-361 | HER2amp | Luminal | Sulindac sulfide | COX1/2 | COX | 10643.136 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0432 | -6.6439 | 0.5141 | |
MDA-MB-231 | TNBC | Basal B | Sirolimus | MTOR | MTOR | 7504.069 | uM | inf | inf | 1.0328 | 1.0328 | 0.0000 | -0.0478 | -66.7663 | 1.8361 | |
HCC1428 | HR+ | Luminal | PS-1145 | IKK | NFKB | 7442.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0407 | -6.6988 | 0.7805 | |
Hs 578T | TNBC | Basal B | Methotrexate | DHFR | Metabolism | 7475.084 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0415 | -7.3003 | 2.7804 | |
SUM159PT | TNBC | Basal B | PS-1145 | IKK | NFKB | 7531.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0370 | -7.5867 | 3.4461 | |
HBL-100 | Unknown | Unknown | Cetuximab | EGFR | ErbB | 7807.042 | uM | inf | inf | 1.0098 | 1.0098 | 0.0000 | -0.0392 | -7.7987 | 2.0250 | |
MDA-MB-415 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7510.094 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0419 | -8.1247 | 0.8152 | |
UACC-812 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 10267.026 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0438 | -8.1346 | 0.3125 | |
MCF 10A | NM | Basal B | PS-1145 | IKK | NFKB | 7484.065 | uM | inf | inf | 1.0207 | 1.0207 | 0.0000 | -0.0389 | -8.5103 | 2.3857 | |
MX1 | Unknown | Unknown | PS-1145 | IKK | NFKB | 7523.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0407 | -9.0127 | 0.7668 | |
Hs 578T | TNBC | Basal B | Purvalanol A | CDK1 | CDK | 7475.067 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0408 | -9.2547 | 2.4078 | |
HCC1569 | HER2amp | Basal A | PD 98059 | MEK | MAPK | 12523.152 | uM | inf | inf | 1.0310 | 1.0310 | 0.0000 | -0.0401 | -9.8795 | 0.8423 | |
SUM225CWN | HER2amp | Basal A | Celecoxib | COX2 | COX | 10579.136 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.6876 | |
BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9186.026 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.5108 | |
MDA-MB-436 | TNBC | Basal B | LY294002 | PI3K | PI3K | 7898.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7130 | |
Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 7475.091 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 2.6839 | |
SUM1315MO2 | TNBC | Basal B | GSK1838705A | IGF1R | RTK | 7528.071 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.5828 | |
BT-20 | TNBC | Basal A | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5904.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.6537 | |
MDA-MB-361 | HER2amp | Luminal | SB-3CT | MMP2/9 | MMP | 12379.168 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.4672 | |
LY2 | HR+ | Luminal | L-779450 | BRAF | MAPK | 10816.149 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.4545 |